SZLSF (StageZero Life Sciences) 5-Year EBITDA Growth Rate: 0.00% (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZLSF StageZero Life Sciences Ltd SZLSF
10 GF Score
Price $0.00
View Full Analysis

What is StageZero Life Sciences 5-Year EBITDA Growth Rate?

StageZero Life Sciences SZLSF 10 5-Year EBITDA Growth Rate is 0.00% as of Sep. 2024. GuruFocus rates SZLSF with a GF Score™ of 10/100.

StageZero Life Sciences's EBITDA per Share for the three months ended in Sep. 2024 was $-0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

StageZero Life Sciences  (OTCPK:SZLSF) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

StageZero Life Sciences 5-Year EBITDA Growth Rate Related Terms

SZLSF vs IDTA, TTOO, NSTM: 5-Year EBITDA Growth Rate Comparison

For the Diagnostics & Research subindustry, StageZero Life Sciences's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StageZero Life Sciences 5-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's 5-Year EBITDA Growth Rate falls into.


SZLSF
10GF Score
StageZero Life Sciences Ltd SZLSF
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StageZero Life Sciences 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
StageZero Life Sciences (SZLSF) has a 5-Year EBITDA Growth Rate of 0.00% as of Sep. 2024. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for StageZero Life Sciences and its competitors.
Is StageZero Life Sciences' 5-Year EBITDA Growth Rate too high?
StageZero Life Sciences' current 5-Year EBITDA Growth Rate is 0.00%. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does StageZero Life Sciences' 5-Year EBITDA Growth Rate compare to IDTA and TTOO?
StageZero Life Sciences' 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
A good 5-Year EBITDA Growth Rate depends on the Medical Diagnostics & Research industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for StageZero Life Sciences and its competitors. StageZero Life Sciences's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StageZero Life Sciences stock overvalued right now?
StageZero Life Sciences (SZLSF) has a current 5-Year EBITDA Growth Rate of 0.00%. The current 5-Year EBITDA Growth Rate is 0.00%. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For StageZero Life Sciences (SZLSF), the current 5-Year EBITDA Growth Rate is 0.00% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StageZero Life Sciences Business Description

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score

Get the complete analysis for SZLSF

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price